Advagene Biopharma Co. Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan.
Market Cap & Net Worth: Advagene Biopharma Co. Ltd. (6709)
Advagene Biopharma Co. Ltd. (TWO:6709) has a market capitalization of $53.93 Million (NT$1.78 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #24011 globally and #1451 in its home market, demonstrating a -2.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Advagene Biopharma Co. Ltd.'s stock price NT$30.05 by its total outstanding shares 59380000 (59.38 Million).
Advagene Biopharma Co. Ltd. Market Cap History: 2018 to 2026
Advagene Biopharma Co. Ltd.'s market capitalization history from 2018 to 2026. Data shows growth from $45.86 Million to $53.93 Million (2.08% CAGR).
Advagene Biopharma Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Advagene Biopharma Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6709 by Market Capitalization
Companies near Advagene Biopharma Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Advagene Biopharma Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Advagene Biopharma Co. Ltd. Historical Marketcap From 2018 to 2026
Between 2018 and today, Advagene Biopharma Co. Ltd.'s market cap moved from $45.86 Million to $ 53.93 Million, with a yearly change of 2.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$53.93 Million | +7.13% |
| 2025 | NT$50.34 Million | +36.83% |
| 2024 | NT$36.79 Million | -21.76% |
| 2023 | NT$47.02 Million | -11.88% |
| 2022 | NT$53.36 Million | -38.46% |
| 2021 | NT$86.71 Million | +47.50% |
| 2020 | NT$58.78 Million | +66.62% |
| 2019 | NT$35.28 Million | -23.08% |
| 2018 | NT$45.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Advagene Biopharma Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.93 Million USD |
| MoneyControl | $53.93 Million USD |
| MarketWatch | $53.93 Million USD |
| marketcap.company | $53.93 Million USD |
| Reuters | $53.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.